Unjoni Ewropea - Malti - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - imipenem monohydrate, cilastatin tas-sodju, relebactam monohydrate - gram-negattivi infezzjonijiet tal-batterji - carbapenems, antibacterials for systemic use, - recarbrio is indicated for:- treatment of hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap), in adults (see sections 4. 4 u 5. - treatment of bacteraemia that occurs in association with, or is suspected to be associated with hap or vap, in adults. - treatment of infections due to aerobic gram-negative organisms in adults with limited treatment options (see sections 4. 2, 4. 4, u 5. għandha tingħata kunsiderazzjoni għall-gwida uffiċjali dwar l-użu xieraq ta ' sustanzi antibatteriċi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

menarini international operations luxembourg s.a. - meropenem trihydrate, vaborbactam - urinary tract infections; bacteremia; bacterial infections; respiratory tract infections; pneumonia; pneumonia, ventilator-associated - antibatteriċi għal użu sistemiku, - vaborem huwa indikat għall-kura ta 'l-infezzjonijiet li ġejjin fl-adulti:ikkumplikati fl-apparat urinarju infezzjoni (cuti), inkluż pyelonephritiscomplicated intra-addominali infezzjoni (ciai)isptar' pnewmonja akkwiżita (hap), inkluż il-ventilatur assoċjati pnewmonja (vap). it-trattament ta 'pazjenti b'batterimja li jiġri f'assoċjazzjoni ma', jew ikun hemm suspett li jkunu assoċjati ma', kwalunkwe ta ' l-infezzjonijiet elenkati hawn fuq. vaborem huwa wkoll indikat għall-kura ta 'infezzjonijiet minħabba aerobiċi gram-negattivi organiżmi fl-adulti bil-limitat għażliet ta' trattament. għandha tingħata kunsiderazzjoni għall-gwida uffiċjali dwar l-użu xieraq ta ' sustanzi antibatteriċi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

akebia europe limited - kumpless ta 'koordinazzjoni taċ-ċitrat ferriku - hyperphosphatemia; renal dialysis - drogi għat-trattament ta 'iperkalimja u iperfosfatemija - fexeric huwa indikat għall-kontroll ta 'iperfosfatemija f'pazjenti adulti b'mard kroniku tal-kliewi (ckd).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - guanfacine hydrochloride - tnaqqis tad-defiċit ta 'l-attenzjoni b'hérapectivity - antiadrenergic agents, centrally acting, antihypertensives, - intuniv is indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. intuniv għandhom ikunu użati bħala parti minn komprensiva adhd-programm tat-trattament, tipikament inkluż psikoloġiċi, l-edukazzjoni u l-miżuri soċjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi winthrop industrie - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - aġenti antitrombotiċi - duoplavin huwa indikat għall-prevenzjoni sekondarja ta 'avvenimenti aterotrombotiċi f'pazjenti adulti li diġà qegħdin jieħdu clopidogrel u acetylsalicylic acid (asa). duoplavin is a fixed-dose combination medicinal product for continuation of therapy in:non st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention (pci);st segment elevation acute myocardial infarction (stemi) in patients undergoing a stent placement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy. għall-aktar informazzjoni jekk jogħġbok irreferi għal sezzjoni 5.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

merck sharp & dohme b.v. - ertapenem sodium - community-acquired infections; streptococcal infections; staphylococcal infections; gram-negative bacterial infections; surgical wound infection; pneumonia, bacterial - antibatteriċi għal użu sistemiku, - treatmenttreatment ta ' l-infezzjonijiet meta jkunu kkawżati minn batterji li huma magħrufa jew x'aktarx li jkunu suxxettibbli għal ertapenem u meta t-terapija parenterali hija meħtieġa:infezzjonijiet intra-addominali;pnewmonja akkwiżita fil-komunità;l-infezzjonijiet ġinekoloġiċi akuti;infezzjonijiet dijabetiċi fis-saqajn tal-ġilda u tat-tessut artab. preventioninvanz huwa indikat fl-adulti għall-profilassi ta'infezzjoni fis-sit kirurġiku wara operazzjoni mhux obbligatorja tal-kolorektum-kirurġija. għandha tingħata kunsiderazzjoni għall-gwida uffiċjali dwar l-użu xieraq ta ' sustanzi antibatteriċi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

mylan pharmaceuticals limited - acetylsalicylic acid, clopidogrel hydrogen sulfate - acute coronary syndrome; myocardial infarction - aġenti antitrombotiċi - clopidogrel/acetylsalicylic acid mylan huwa indikat għall-prevenzjoni sekondarja ta ' avvenimenti aterotrombotiċi f'pazjenti adulti li diġà qed jieħdu ż-żewġ clopidogrel u acetylsalicylic acid (asa). clopidogrel/acetylsalicylic acid mylan huwa kombinazzjoni b'doża fissa tal-prodott mediċinali għall-kontinwazzjoni tat-terapija:mhux elevazzjoni tas-segment st sindromu koronarju akut (anġina instabbli jew mhux-mewġa-q infart mijokardijaku) li jinkludu pazjenti fi proċess li titpoġġa stent wara koronarju perkutanju interventionst elevazzjoni tas-segment infart mijokardijaku akut fil-medikament pazjenti kkurati b'eliġibbli għat-terapija trombolitika.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sun pharmaceutical industries (europe) b.v. - ertapenem sodium - infezzjonijiet batteriċi - ertapenem - treatmentertapenem sun is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required (see sections 4. 4 u 5. 1):- intra-abdominal infections- community acquired pneumonia- acute gynaecological infections- diabetic foot infections of the skin and soft tissue (see section 4. 4)preventionertapenem sun is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4. għandha tingħata kunsiderazzjoni għall-gwida uffiċjali dwar l-użu xieraq ta ' sustanzi antibatteriċi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer europe ma eeig - tigecycline - bacterial infections; skin diseases, bacterial; soft tissue infections - antibatteriċi għal użu sistemiku, - tygacil is indicated in adults and in children from the age of eight years for the treatment of the following infections: , complicated skin and soft tissue infections (cssti), excluding diabetic foot infections, complicated intra-abdominal infections (ciai) , tygacil should be used only in situations where other alternative antibiotics are not suitable. għandha tingħata kunsiderazzjoni għall-gwida uffiċjali dwar l-użu xieraq ta ' sustanzi antibatteriċi. l-użu xieraq ta ' sustanzi antibatteriċi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bioprojet pharma - pitolisant - narcolepsy - drogi oħra tas-sistema nervuża - wakix is indicated in adults, adolescents and children from the age of 6 years for the treatment of narcolepsy with or without cataplexy (see also section 5.